Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
Fennec Pharmaceuticals Inc. Chief Medical Officer Pierre Sargis Sayad had 168 Common Shares released from restriction on September 30, 2026, from shares awarded March 28, 2025. His direct holdings after the transaction were 9,687 shares. The transaction is reported as an award-related acquisition, rather than a market purchase; no Rule 10b5-1 plan is reported.
Fennec Pharmaceuticals Inc. Chief Commercial Officer Terry L. Evans reported an acquisition of 168 common shares on September 30, 2026. The shares were released from restriction from shares awarded March 28, 2025. Evans held 21,687 common shares directly after the transaction.
Fennec Pharmaceuticals Inc. (FENC) Chief Executive Officer Jeffrey S. Hackman had 1,159 Common Shares released from restriction on September 30, 2026. The shares came from an award dated March 28, 2025. After the transaction, he directly held 67,461 Common Shares. The reported action was an award-related acquisition.
Fennec Pharmaceuticals Inc. Chief Strategy Officer Christiana Marie Cioffi acquired 156 common shares on September 30, 2026, as shares released from restriction from shares awarded March 28, 2025. She directly held 24,800 shares following the transaction. The reported per-share price was $0.0000; this was an award-related restriction release, not a market purchase.
Fennec Pharmaceuticals Inc. Chief Financial Officer Robert Andrade reported acquiring 1,703 common shares on September 30, 2026. The shares were released from restriction from awards dated May 16, 2024, and March 28, 2025. His reported direct holdings after the transaction were 243,009 common shares; the reported per-share price was $0.0000.
Fennec Pharmaceuticals Inc. (FENC) reported positive top-line data from the investigator-initiated Phase 2 STS-J01 study of PEDMARK in Japan. The trial met its primary endpoint, with American Speech-Language-Hearing Association–defined hearing loss in 24.0% of patients versus a prespecified historical benchmark of 56.4% (p=0.001), showing substantial hearing protection.
Additional results showed 84% of patients had Grade 0 hearing loss by Brock criteria, with no Grade 3 or 4 hearing loss, and objective tumor responses in 23 of 24 evaluable patients (95.8%), supporting lack of interference with cisplatin antitumor activity. The study enrolled 33 patients across 11 Japanese institutions. Fennec states it is pursuing registration in Japan and is exploring partnering or licensing opportunities for PEDMARK.
FENNEC PHARMACEUTICALS INC. (FENC) director Marco Maria Brughera exercised stock options for 15,545 common shares on September 15, 2026 at an exercise price of $2.11 per share and sold 15,545 common shares at $10.29 per share, all pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2026. Following the option exercise, he held 220,000 stock options directly.
FENNEC PHARMACEUTICALS INC. (FENC) received a notice that director Marco Maria Brughera plans to sell common shares under Rule 144. The filing covers 15,545 shares of common stock, with an aggregate market value of $160,069.97, expected to be sold on or about September 15, 2026 on NASDAQ.
The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, and the planned transaction is described as a stock option exercise settled in cash. The notice also lists transaction dates in the prior three months, including June 16, 2026.
FENNEC PHARMACEUTICALS INC. (FENC) has a notice from former director Rostislav Raykov to sell common shares under Rule 144. The planned sale covers 10,000 common shares through Morgan Stanley Smith Barney LLC, with an estimated aggregate market value of $121,177.00, at a time when 35,067,159 common shares were outstanding and the stock traded on NASDAQ.
The shares to be sold were acquired as restricted stock from the issuer during the period from 11/30/2025 through 02/28/2026, with an acquisition date listed as 11/30/2025 for 10,000 shares. In the prior three months, Raykov sold 10,000 common shares on 08/03/2026 for $95,835.00 and 9,599 common shares on 07/01/2026 for $99,987.02.
FENNEC PHARMACEUTICALS INC. (FENC) reported that former director Rosty Raykov had two non-derivative transactions in common shares. On 2026-08-31, he acquired 2,778 common shares at $0.00 per share, representing shares released from restriction from an award granted on May 16, 2024. On 2026-09-01, he sold 10,000 common shares at $12.11 per share in a transaction described as a sale in the open market or a private transaction, executed pursuant to a Rule 10b5-1 trading plan dated September 19, 2025.